PI3K p85 β regulatory subunit deficiency does not affect NK cell differentiation and increases NKG2D‐mediated activation. Issue 6 (5th July 2016)

• Record Type: Journal Article
• Authors: Rojas, José M.; Spada, Roberto; Sanz‐Ortega, Laura; Morillas, Laura; Mejías, Raquel; Mulens‐Arias, Vladimir; Pérez‐Yagüe, Sonia; Barber, Domingo F.
• Is Part Of: Journal of leukocyte biology. Volume 100:Issue 6(2016)
• Page Start: 1285
• Page End: 1296
• Publication Date: 2016-07-05
• Subjects: phosphoinositide‐3‐kinase -- DAP10 -- degranulation -- IFN‐γ -- Cbl; Leucocytes -- Periodicals; Reticulo-endothelial system -- Periodicals; 571.96
• DOI: 10.1189/jlb.1A1215-541RR
• Languages: English
• ISSNs: 0741-5400

Abstract

Abstract : Deficiency of the p85β regulatory subunit of PI3K does not affect NK cell differentiation and increases NK cell activity. Abstract : Activation of NK cells depends on a balance between activating and inhibitory signals. Class Ia PI3K are heterodimeric proteins with a catalytic and a regulatory subunit and have a central role in cell signaling by associating with tyrosine kinase receptors to trigger signaling cascades. The regulatory p85 subunit participates in signaling through NKG2D, one of the main activating receptors on NK cells, via its interaction with the adaptor protein DAP10. Although the effects of inhibiting catalytic subunits or deleting the regulatory p85α subunit have been studied, little attention has focused on the role of the p85β subunit in NK cells. Using p85β knockout mice, we found that p85β deficiency does not alter NK cell differentiation and maturation in spleen or bone marrow. NK cells from p85β −/− mice nonetheless produced more IFN‐γ and degranulated more effectively when stimulated with anti‐NKG2D antibody. These cells also degranulated and killed NKG2D ligand‐expressing target cells more efficiently. We show that p85β deficiency impaired NKG2D internalization, which could contribute to the activated phenotype. Decreasing p85β subunit protein levels might thus constitute a therapeutic target to promote NK cell activity toward NKG2D ligand‐expressing cells.